MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/03007995.2025.2465615

Медицинская библиотека · Current medical research and opinion · 2025

Resistance to conventional drug therapy and good response to lomitapide allowed the identification of a novel bi-allelic semi-dominant monogenic HoFH: a case report.

Fornengo Paolo, Mattivi Simone, Rinaudo Elisa, Lepore Federica, Iemmolo Ileana, Bracciamà Valeria, Del Prever Giulia Margherita Brach, Faini Angelo Corso, Durazzo Marilena, Deaglio Silvia

СтатьяКлинический случайПеревод пока не подготовлен

Аннотация

INTRODUCTION

Familial hypercholesterolaemia (FH) is a genetic disorder associated with high cholesterol levels and an increased risk of premature cardiovascular events. Rare forms, such as semi-dominant bi-allelic mutations, pose diagnostic and therapeutic challenges. Misdiagnosis of FH is a significant concern, as highlighted by both this case and a review of the literature.

CASE REPORT: We report the case of a 54-year-old woman with an acute myocardial infarction at the age of 43 years. She had a positive family history of early cardiovascular events and was diagnosed with familial hypercholesterolaemia at the age of 33 years. She tried statins with no benefit. In 2017, evolocumab was introduced but was insufficient to control cholesterol values (low-density lipoprotein cholesterol 324 mg/dL). She started lomitapide, and next-generation sequencing screening was performed in consideration of the different pharmacological effects and clinical trends compared to other family members. A bi-allelic semi-dominant mutation (c.241C > T in exon 3 of the LDLR gene) was found in addition to the previously identified mutation. She is now in good clinical condition and laboratory response with lomitapide, evolocumab, statin, and ezetimibe. A literature review was conducted to explore the clinical and diagnostic challenges of FH, with a focus on the risk of misdiagnosis.

CONCLUSION

This case underscores the importance of genetic testing in diagnosing rare forms of FH, such as semi-dominant bi-allelic mutations, which may lead to misdiagnosis. Lomitapide proved effective in controlling cholesterol levels, highlighting its value in managing complex FH cases. The literature review further emphasizes the critical need for improved diagnostic approaches to minimize the risk of misdiagnosis.

Для цитирования: Fornengo Paolo, Mattivi Simone, Rinaudo Elisa, Lepore Federica, Iemmolo Ileana, Bracciamà Valeria, Del Prever Giulia Margherita Brach, Faini Angelo Corso, Durazzo Marilena, Deaglio Silvia. Resistance to conventional drug therapy and good response to lomitapide allowed the identification of a novel bi-allelic semi-dominant monogenic HoFH: a case report.. Current medical research and opinion. 2025. DOI: 10.1080/03007995.2025.2465615.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.